Hepion Pharmaceuticals 将来の成長

Future 基準チェック /06

Hepion Pharmaceuticalsの収益は年間23.5%で減少すると予測されていますが、年間収益は年間90.4%で増加すると予想されています。EPS は年間9.2%で増加すると予想されています。

主要情報

-23.5%

収益成長率

9.2%

EPS成長率

Pharmaceuticals 収益成長	21.4%
収益成長率	90.4%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	23 May 2023

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

DB:336 - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	N/A	-82	-73	N/A	2
12/31/2024	N/A	-62	-45	N/A	2
12/31/2023	N/A	-51	-10	N/A	2
3/31/2023	N/A	-52	-33	-33	N/A
12/31/2022	N/A	-45	-35	-35	N/A
9/30/2022	N/A	-45	-38	-38	N/A
6/30/2022	N/A	-46	-36	-36	N/A
3/31/2022	N/A	-34	-34	-34	N/A
12/31/2021	N/A	-33	-31	-31	N/A
9/30/2021	N/A	-28	-29	-28	N/A
6/30/2021	N/A	-25	-21	-21	N/A
3/31/2021	N/A	-22	-19	-19	N/A
12/31/2020	N/A	-20	-16	-16	N/A
9/30/2020	N/A	-18	-14	-14	N/A
6/30/2020	N/A	-13	-12	-12	N/A
3/31/2020	N/A	-15	-10	-10	N/A
12/31/2019	N/A	-12	-8	-8	N/A
9/30/2019	N/A	-12	-10	-10	N/A
6/30/2019	N/A	-20	-12	-12	N/A
3/31/2019	N/A	-17	-14	-14	N/A
12/31/2018	N/A	-18	-16	-16	N/A
9/30/2018	N/A	-17	-13	-13	N/A
6/30/2018	N/A	-14	-15	-15	N/A
3/31/2018	N/A	-8	-16	-16	N/A
12/31/2017	N/A	-13	-18	-18	N/A
9/30/2017	N/A	-16	-20	-20	N/A
6/30/2017	N/A	-15	-19	-19	N/A
3/31/2017	N/A	-22	-19	-19	N/A
12/31/2016	N/A	-18	N/A	-18	N/A
9/30/2016	N/A	-17	N/A	-18	N/A
6/30/2016	N/A	-17	N/A	-17	N/A
3/31/2016	N/A	-17	N/A	-16	N/A
12/31/2015	N/A	-21	N/A	-15	N/A
9/30/2015	N/A	-26	N/A	-11	N/A
6/30/2015	N/A	-22	N/A	-10	N/A
3/31/2015	N/A	-12	N/A	-6	N/A
12/31/2014	N/A	-14	N/A	-4	N/A
9/30/2014	N/A	-7	N/A	-2	N/A
6/30/2014	N/A	-5	N/A	-1	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 336今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 336今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: 336今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 336来年は収益がないと予測されています。

高い収益成長: 336来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 336の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Hepion Pharmaceuticals 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

Hepion Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Regarding Stockholder's Deficit

Hepion Pharmaceuticals Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2)

Pharma Two B Ltd. agreed to acquire Hepion Pharmaceuticals, Inc. (NasdaqCM:HEPA) in a reverse merger transaction valued at an implied equity value of approximately $58.5 million.

Hepion Pharmaceuticals, Inc. announced delayed 10-Q filing

Hepion Pharmaceuticals, Inc. Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial

Hepion Pharmaceuticals, Inc. announced delayed annual 10-K filing

Hepion Pharmaceuticals, Inc. Appoints Michael Purcell to Its Board of Directors

Hepion Pharmaceuticals, Inc. Announces Resignation of Anand Reddi from the Board of Directors

Hepion Pharmaceuticals, Inc. Announces Resignation of Robert Foster as Director

Hepion Pharmaceuticals, Inc. announced delayed 10-Q filing

Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-Week Phase 2 Study of Advanced (F3) Mash Liver Disease

Hepion Pharmaceuticals, Inc. Announces the Publication of New Research Study in Mice

Hepion Pharmaceuticals, Inc. announced that it has received $5.000004 million in funding

Hepion Pharmaceuticals, Inc. Announces Results from A Study with in Which the Anti-Cancer Activity of Hepion's Lead Drug Candidate, Rencofilstat

Hepion Pharmaceuticals, Inc. Announces Positive Results from Translational Research Study

Hepion Pharmaceuticals, Inc. Announces Resignation of Dr. Todd Hobbs, as the Chief Medical Officer, Effective September 29, 2023

Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat

Hepion Pharmaceuticals, Inc. Announces Positive Topline Results from Its Recently Completed Phase 2 Altitude-Nash Clinical Trial

High number of new directors

Hepion Pharmaceuticals, Inc. Announces Positive Results of Preclinical Studies Examining Rencofilstat as A Potential Therapeutic for Multiple Myeloma

Hepion Pharmaceuticals, Inc. Presents of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors

Hepion Pharmaceuticals Receives 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirements

Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 'Altitude-Nash' Liver Function Trial

Hepion Pharmaceuticals, Inc. Announces Publication of Phase 2A 'Ambition' Clinical Trial Results

Hepion Pharmaceuticals, Inc. Announces Initiation of Dosing in Phase 2 'ALTITUDE-NASH' Liver Function Trial

Hepion Pharmaceuticals, Inc. Announces Initiation of Phase 2b ‘ASCEND-NASH’ Trial

Hepion Pharmaceuticals, Inc., Annual General Meeting, Aug 05, 2022

Hepion Pharmaceuticals, Inc. Announces Board Changes

Hepion Pharmaceuticals, Inc. Appoints Dr. Launa J. Aspeslet as Chief Operating Officer

Hepion Pharmaceuticals Receives Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard from Nasdaq

Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial

Hepion Pharmaceuticals, Inc., Annual General Meeting, Jun 24, 2022

Hepion Pharmaceuticals, Inc. announced delayed annual 10-K filing

Hepion Pharmaceuticals Appoints Eddie C. Cheung to Lead the Company’s Strategic Medical Affairs in Asia

Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer

Hepion Pharmaceuticals, Inc Announces Additional Efficacy Data from Its Phase 2A Ambition Clinical Trial

Hepion Pharmaceuticals, Inc. Announces Positive Topline Data from Phase 2A ‘Ambition’ Nash Trial and Achieve All Primary Endpoints

Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2A 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH

Hepion Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $88.4 million.

Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer

Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH

Hepion Pharmaceuticals’ CRV431 Demonstrates Additional Potential Advantage in Liver Disease

Hepion Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Hepion Pharmaceuticals Terminated the At Market Issuance Sales Agreement with B. Riley FBR, Inc

New 90-day low: €2.22

Hepion Pharmaceuticals, Inc.'s Data Safety Monitoring Board Recommends Continuation of Phase 2A 'Ambition' Clinical Trial for Treatment of Advanced Nash

New 90-day low: €2.44

Hepion Pharmaceuticals Introduces Proprietary A.I. Platform for Drug Development

Hepion Pharmaceuticals Reports Positive Activity of CRV431 Against Coronavirus SARS-2 in Study Conducted by the National Institute of Allergy and Infectious Diseases

New 90-day high - €3.76

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘